The average price of dasatinib in the USA can vary significantly based on dosage, quantity, and pharmacy. Without specific prescription details, providing an exact figure is challenging. However, cash prices for a 30-day supply can range from several thousand dollars.
What factors influence dasatinib pricing?
The cost of dasatinib is influenced by several factors, including the specific formulation and strength prescribed, the quantity purchased (e.g., 30-day or 90-day supply), and the retail pharmacy chosen. Brand-name dasatinib, marketed as Sprycel, generally carries a higher price tag than its generic counterparts [1]. Insurance coverage also plays a crucial role, with copayments and deductibles impacting the out-of-pocket expense for patients.
How does insurance affect dasatinib costs?
For individuals with health insurance, the actual cost of dasatinib is determined by their specific plan's formulary, deductible, and copayment structure. Insurers may have preferred generics or require prior authorization for the medication. Patients often find their out-of-pocket expenses are significantly lower with comprehensive insurance coverage compared to paying the full cash price.
Are there ways to get dasatinib at a lower cost?
Patients may explore several avenues to reduce the cost of dasatinib. These can include using discount cards or coupons from pharmaceutical manufacturers or third-party discount providers. Comparing prices across different pharmacies, including online pharmacies, can also lead to savings. For eligible individuals, patient assistance programs offered by pharmaceutical companies or non-profit organizations may provide financial support.
When does dasatinib patent exclusivity expire?
Patent exclusivity for dasatinib has been a complex area. While primary patents may have expired or are nearing expiration, secondary patents, such as those related to new formulations or methods of use, can extend market protection. Information on specific patent expiry dates and any ongoing litigation can be found through resources that track drug patents [2].
Who makes generic dasatinib?
Following the expiration of key patents, several pharmaceutical companies have entered the market with generic versions of dasatinib. These manufacturers are typically approved by the U.S. Food and Drug Administration (FDA) and must demonstrate that their generic product is bioequivalent to the brand-name drug. Companies like Teva, Viatris (formerly Mylan), and others are known to produce generic dasatinib.
What are the clinical indications for dasatinib?
Dasatinib is a tyrosine kinase inhibitor primarily used to treat certain types of leukemia. Its main indications include the treatment of chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), as well as Ph+ acute lymphoblastic leukemia (ALL) [1].
Sources:
1. DrugPatentWatch.com
2. https://drugpatentwatch.com/drug/dasatinib